Table 1 Patient and breast tumour characteristics
Parameter | Group S | Group SL | Group P | Group PL |
|---|---|---|---|---|
Sevoflurane | Sevoflurane + lidocaine | Propofol-TIVA | Propofol-TIVA + lidocaine | |
(n = 29) | (n = 30) | (n = 30) | (n = 30) | |
Age (yr) | 50.3(9.3) | 53.6(10.5) | 51.1(7.8) | 50.5(8.1) |
BMI (kg m2) | 23.3(3.1) | 23.5(2.7) | 24.5(2.9) | 23.8(2.4) |
ASA physical status (n,%) | ||||
I | 8(28) | 7(23) | 5(17) | 6(20) |
II | 21(72) | 23(77) | 25(83) | 24(80) |
Hypertensive (n,%) | 2(7) | 6(20) | 5(17) | 3(10) |
Preoperative NACT (n,%) | 3(10) | 2(7) | 1(3) | 1(3) |
Tumour site (n,%) | ||||
Left | 13(45) | 11(37) | 15(50) | 19(63) |
Right | 16(55) | 19(63) | 15(50) | 11(37) |
TNM classification | ||||
Pathology stage, tumour (n,%) | ||||
Tis | 1(3) | 2(7) | 2(7) | 3(10) |
T0 | 0 | 1(3) | 0 | 0 |
T1 | 18(62) | 17(57) | 20(67) | 19(63) |
T2 | 10(35) | 10(33) | 8(27) | 8(27) |
Pathology stage, nodes (n,%) | ||||
N0 | 18(62) | 20(67) | 16(53) | 23(77) |
N1 | 7(24) | 5(17) | 10(33) | 4(13) |
N2 | 2(7) | 4(13) | 2(7) | 2(7) |
N3 | 2(7) | 1(3) | 2(7) | 1(3) |
Pathology stage, metastasis (n,%) | ||||
M0 | 29(100) | 30(100) | 30(100) | 30(100) |
Tumour TNM stage (n,%) | ||||
0 | 1(3) | 2(7) | 2(7) | 3(10) |
I | 12(41) | 12(40) | 11(37) | 17(57) |
II | 12(41) | 11(37) | 13(43) | 7(23) |
III | 4(14) | 5(17) | 4(13) | 3(10) |